IOL Chemicals & Pharmaceuticals Ltd consolidated sales up 5.13% on year in Q3FY2026,
IOL Chemicals & Pharmaceuticals Ltd share price softened by 3.84% to Rs 177.75. The Company`s net profit grew slightly 1.04% to Rs 65.07 crore, while revenue from operations slightly gained 5.13% to Rs 795.03 crore in Q3FY26 over Q2FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 27.58 lakh crore, gaining 4.48%. It has marginally improved by 6.57% over last one week and ticked higher by 1.39% in last one month while the market capitalization of IOL Chemicals & Pharmaceuticals Ltd has improved by 8.78% and 21.58% in the same period respectively. Profit before tax (PBT) of IOL Chemicals & Pharmaceuticals Ltd stood at Rs 87.29 crore in Q3 FY26, surging by 115.58% year-on-year, and easing 0.69% quarter-on-quarter. EBITDA came in at Rs 104 crore, rallying 106.99% YoY and rising 9.02% sequentially. Total expenses posted a minor rise of 5% to Rs 707.81 crore in Q3FY26 over Q3FY25. During the quarter, cost of materials consumed stood at Rs 505.31 crore, marginally falling by 0.29% YoY, while employee benefits expense was at Rs 68.71 crore, softening 3.51% YoY. For the TTM ended FY26, revenue from operations advanced 11.54% to Rs 2319.06 crore, while net profit jumped 36.18% to Rs 137.64 crore, compared to previous TTM. EBITDA surged by 18713% to Rs 247.59 crore, and PBT surged 33.63% to Rs 184.36 crore compared to previous TTM. The company`s consolidated net cash flow from operating activities stood at Rs 214.32 crore in FY26, as against Rs 178.62 crore in FY25. IOL Chemicals & Pharmaceuticals Ltd rallied 90.41% in last one year, significantly outperforming the benchmark BSE Sensex which has slipped by 11.78% during the same period.
IOL Chemicals & Pharmaceuticals Ltd consolidated sales up 22.09% on year in Q2FY2026, net profit saw a strong growth of 21.14%,
IOL Chemicals & Pharmaceuticals Ltd share price inched up 2.35% to Rs 184.85 after the company`s net profit soared by 21.14% to Rs 64.4 crore, while revenue from operations gained significantly 22.09% to Rs 756.26 crore in Q2FY26 over Q1FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 27.58 lakh crore, easing 4.54%. It has marginally improved by 5.74% over last one week and gained upto 0.60% in last one month while the market capitalization of IOL Chemicals & Pharmaceuticals Ltd has gained 13.13% and 26.44% in the same period respectively. Profit before tax (PBT) of IOL Chemicals & Pharmaceuticals Ltd stood at Rs 86.69 crore in Q2 FY26, jumping 90.49% year-on-year, and surging by 22.43% quarter-on-quarter. EBITDA came in at Rs 95 crore, expanding by 74.02% YoY and rising 5.16% sequentially. Total expenses surged 23.18% to Rs 674.11 crore in Q2FY26 over Q2FY25. During the quarter, cost of materials consumed stood at Rs 506.76 crore, soaring by 26.17% YoY, while employee benefits expense was at Rs 71.21 crore, inching up 1.25% YoY. For the TTM ended FY26, revenue from operations grew 11.54% to Rs 2319.06 crore, while net profit jumped 36.18% to Rs 137.64 crore, compared to previous TTM. EBITDA jumped by 18713% to Rs 247.59 crore, and PBT soared 33.63% to Rs 184.36 crore compared to previous TTM. The company`s consolidated net cash flow from operating activities stood at Rs 214.32 crore in FY26, as against Rs 178.62 crore in FY25. IOL Chemicals & Pharmaceuticals Ltd surged by 95.40% in last one year, significantly outperforming the benchmark BSE Sensex which has declined by 12.76% during the same period.
IOL Chemicals and Pharmaceuticals reports certificate compliance with SEBI regulations,
IOL Chemicals and Pharmaceuticals Limited informed the National Stock Exchange of India Ltd. and BSE Limited that it received a certificate from M/s. Alankit Assignment Limited, its Registrar and Share Transfer Agent, in compliance with Regulation 74(5) of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018, for the quarter ended 30th September 2026.
IOL Chemicals restricts trading for insiders ahead of September 2026 financial results,
IOL Chemicals and Pharmaceuticals Limited will close its trading window for designated persons and their immediate relatives from October 1, 2026, until 48 hours after the declaration of financial results for the quarter and half year ended September 30, 2026, in compliance with SEBI regulations.
IOL Chemicals & Pharmaceuticals consolidated net profit rises 89.80% in the June 2026 quarter,
Net profit of IOL Chemicals & Pharmaceuticals rose 89.80% to Rs 64.40 crore in the quarter ended June 2026 as against Rs 33.93 crore during the previous quarter ended June 2025. Sales rose 37.08% to Rs 756.26 crore in the quarter ended June 2026 as against Rs 551.69 crore during the previous quarter ended June 2025. ParticularsQuarter EndedJun. 2026Jun. 2025% Var. Sales756.26551.69 37 OPM %13.6811.26 - PBDT108.0365.28 65 PBT86.6945.51 90 NP64.4033.93 90 Powered by Capital Market - Live News
Subscribe for our
newsletter
Open Account Now